Shares of Senseonics Holdings (NYSEMKT: SENS) skyrocketed 340% in the first half of 2021. The stock vaulted more than 500% higher by mid-February, but gave up some of those gains.
One key early catalyst for Senseonics was a positive coverage decision in January by health insurer EmblemHealth for the Eversense continuous glucose-monitoring (CGM) system used by individuals with diabetes. That was just the beginning of the good news for the company, though.